These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

949 related items for PubMed ID: 19781717

  • 21. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS.
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [Abstract] [Full Text] [Related]

  • 22. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA, Roobol MJ, Venderbos LD, Joosten-van Zwanenburg E, Essink-Bot ML, Steyerberg EW, Bangma CH, Korfage IJ.
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [Abstract] [Full Text] [Related]

  • 23. Assessing individual risk for prostate cancer.
    Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW.
    J Clin Oncol; 2007 Aug 20; 25(24):3582-8. PubMed ID: 17704405
    [Abstract] [Full Text] [Related]

  • 24. A framework for the identification of men at increased risk for prostate cancer.
    Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL.
    J Urol; 2009 Nov 20; 182(5):2112-20. PubMed ID: 19758625
    [Abstract] [Full Text] [Related]

  • 25. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen testing.
    Farrell MH, Murphy MA, Schneider CE.
    Eff Clin Pract; 2002 Nov 20; 5(3):120-9. PubMed ID: 12088291
    [Abstract] [Full Text] [Related]

  • 26. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.
    Urology; 2008 May 20; 71(5):787-91. PubMed ID: 18267334
    [Abstract] [Full Text] [Related]

  • 27. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J.
    Jpn J Clin Oncol; 2009 Nov 20; 39(11):727-31. PubMed ID: 19674994
    [Abstract] [Full Text] [Related]

  • 28. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
    Karazanashvili G, Abrahamsson PA.
    J Urol; 2003 Feb 20; 169(2):445-57. PubMed ID: 12544286
    [Abstract] [Full Text] [Related]

  • 29. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
    Sotelo RJ, Mora KE, Pérez LH, Novoa J, Carmona O, De Andrade R, Borges RE, Parada D, Loeb S, Catalona WJ.
    Urology; 2007 Jun 20; 69(6):1143-6. PubMed ID: 17572203
    [Abstract] [Full Text] [Related]

  • 30. Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH.
    Eur Urol; 2008 Sep 20; 54(3):505-16. PubMed ID: 18585845
    [Abstract] [Full Text] [Related]

  • 31. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).
    Oncology (Williston Park); 2000 Feb 20; 14(2):267-72, 277-8, 280 passim. PubMed ID: 10736812
    [Abstract] [Full Text] [Related]

  • 32. A neurocomputational model for prostate carcinoma detection.
    Kalra P, Togami J, Bansal B S G, Partin AW, Brawer MK, Babaian RJ, Ross LS, Niederberger CS.
    Cancer; 2003 Nov 01; 98(9):1849-54. PubMed ID: 14584066
    [Abstract] [Full Text] [Related]

  • 33. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED, Abrahamsson PA.
    Eur Urol; 2008 Aug 01; 54(2):262-73. PubMed ID: 18556114
    [Abstract] [Full Text] [Related]

  • 34. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Hoffman RM, Couper MP, Zikmund-Fisher BJ, Levin CA, McNaughton-Collins M, Helitzer DL, VanHoewyk J, Barry MJ.
    Arch Intern Med; 2009 Sep 28; 169(17):1611-8. PubMed ID: 19786681
    [Abstract] [Full Text] [Related]

  • 35. Prostate cancer early detection clinical practice guidelines in oncology.
    Babaian RJ, Partin AW, National Comprehensive Cancer Network.
    J Natl Compr Canc Netw; 2003 Jan 28; 1 Suppl 1():S42-55. PubMed ID: 19795575
    [Abstract] [Full Text] [Related]

  • 36. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE, Altwein JE.
    MMW Fortschr Med; 2005 Apr 07; 147(14):32, 34-6. PubMed ID: 15887681
    [Abstract] [Full Text] [Related]

  • 37. The Japanese guideline for prostate cancer screening.
    Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T.
    Jpn J Clin Oncol; 2009 Jun 07; 39(6):339-51. PubMed ID: 19346535
    [Abstract] [Full Text] [Related]

  • 38. Prostate specific antigen: an updated review.
    So A, Goldenberg L, Gleave ME.
    Can J Urol; 2003 Dec 07; 10(6):2040-50. PubMed ID: 14704108
    [Abstract] [Full Text] [Related]

  • 39. Randomized trial results did not resolve controversies surrounding prostate cancer screening.
    Hoffman RM.
    Curr Opin Urol; 2010 May 07; 20(3):189-93. PubMed ID: 20224414
    [Abstract] [Full Text] [Related]

  • 40. Update on screening for prostate cancer with prostate-specific antigen.
    Schmid HP, Riesen W, Prikler L.
    Crit Rev Oncol Hematol; 2004 Apr 07; 50(1):71-8. PubMed ID: 15094160
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.